These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 3435107)

  • 1. Pharmacokinetics of cefpiramide in volunteers with normal or impaired renal function.
    Conte JE
    Antimicrob Agents Chemother; 1987 Oct; 31(10):1585-8. PubMed ID: 3435107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of cefpiramide in healthy volunteers, patients with various degrees of renal dysfunction, and patients on hemodialysis.
    Ohkawa M; Tokunaga S; Sugata T; Shimamura M; Okasho A; Hirano S; Matsui H
    Chemotherapy; 1989; 35(6):416-22. PubMed ID: 2612231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cefpiramide kinetics and plasma protein binding in cholestasis.
    Demontes-Mainard F; Vinçon G; Labat L; Amouretti M; Necciari J; Kieffer G; Bannwarth B
    Br J Clin Pharmacol; 1994 Mar; 37(3):295-7. PubMed ID: 8198940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of cefodizime in volunteers with normal or impaired renal function.
    Conte JE
    J Clin Pharmacol; 1994 Nov; 34(11):1066-70. PubMed ID: 7876397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-dose pharmacokinetics of cefpirome in patients with renal impairment.
    Lameire N; Malerczyk V; Drees B; Lehr K; Rosenkranz B
    Clin Pharmacol Ther; 1992 Jul; 52(1):24-30. PubMed ID: 1623690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of cefotetan in normal subjects and patients with impaired renal function.
    Ohkawa M; Hirano S; Tokunaga S; Motoi I; Shoda R; Ikeda A; Sugata T; Sawaki M; Shimamura M; Okasho A; Kuroda K
    Antimicrob Agents Chemother; 1983 Jan; 23(1):31-5. PubMed ID: 6572490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of cefprozil in healthy subjects and patients with renal impairment.
    Shyu WC; Pittman KA; Wilber RB; Matzke GR; Barbhaiya RH
    J Clin Pharmacol; 1991 Apr; 31(4):362-71. PubMed ID: 2037710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple-dose pharmacokinetics of cefonicid in patients with impaired renal function.
    Phelps RT; Conte JE
    Antimicrob Agents Chemother; 1986 May; 29(5):913-7. PubMed ID: 3729349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experimental and clinical evaluation of the biliary pharmacokinetic profile of cefpiramide, a new cephalosporin with high hepatic elimination.
    Brogard JM; Jehl F; Blickle JF; Arnaud JP; Monteil H
    Drugs Exp Clin Res; 1988; 14(8):519-27. PubMed ID: 3248507
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of cefpiramide (SM-1652) in humans.
    Nakagawa K; Koyama M; Matsui H; Ikeda C; Yano K; Nakatsuru N; Yoshinaga K; Noguchi T
    Antimicrob Agents Chemother; 1984 Feb; 25(2):221-5. PubMed ID: 6712202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of cefamandole in patients with renal impairment.
    Czerwinski AW; Pederson JA
    Antimicrob Agents Chemother; 1979 Feb; 15(2):161-4. PubMed ID: 426510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and protein binding of cefpiramide in patients with alcoholic cirrhosis.
    Demotes-Mainard F; Vinçon G; Amouretti M; Dumas F; Necciari J; Kieffer G; Begaud B
    Clin Pharmacol Ther; 1991 Mar; 49(3):263-9. PubMed ID: 2007321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-dose pharmacokinetics of lomefloxacin in patients with normal and impaired renal function.
    Nilsen OG; Saltvedt E; Walstad RA; Marstein S
    Am J Med; 1992 Apr; 92(4A):38S-40S. PubMed ID: 1316068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of cefmetazole in normal subjects and in patients with impaired renal function.
    Ohkawa M; Orito M; Sugata T; Shimamura M; Sawaki M; Nakashita E; Kuroda K; Sasahara K
    Antimicrob Agents Chemother; 1980 Sep; 18(3):386-9. PubMed ID: 6932824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of cefoperazone (2.0 g) and sulbactam (1.0 g) coadministered to subjects with normal renal function, patients with decreased renal function, and patients with end-stage renal disease on hemodialysis.
    Reitberg DP; Marble DA; Schultz RW; Whall TJ; Schentag JJ
    Antimicrob Agents Chemother; 1988 Apr; 32(4):503-9. PubMed ID: 3377461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of cefepime in subjects with renal insufficiency.
    Barbhaiya RH; Knupp CA; Forgue ST; Matzke GR; Guay DR; Pittman KA
    Clin Pharmacol Ther; 1990 Sep; 48(3):268-76. PubMed ID: 2401125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of decreased renal function on the pharmacokinetics of ceftazidime.
    Ackerman BH; Ross J; Tofte RW; Rotschafer JC
    Antimicrob Agents Chemother; 1984 Jun; 25(6):785-6. PubMed ID: 6378087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of ceftizoxime in subjects with various degrees of renal function.
    Kowalsky SF; Echols RM; Venezia AR; Andrews EA
    Antimicrob Agents Chemother; 1983 Aug; 24(2):151-5. PubMed ID: 6314884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function.
    Aweeka F; Jayesekara D; Horton M; Swan S; Lambrecht L; Wilner KD; Sherwood J; Anziano RJ; Smolarek TA; Turncliff RZ
    Br J Clin Pharmacol; 2000; 49 Suppl 1(Suppl 1):27S-33S. PubMed ID: 10771451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of meropenem in subjects with various degrees of renal impairment.
    Christensson BA; Nilsson-Ehle I; Hutchison M; Haworth SJ; Oqvist B; Norrby SR
    Antimicrob Agents Chemother; 1992 Jul; 36(7):1532-7. PubMed ID: 1510451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.